Knee Stem Cell Therapy in China: A Non-Surgical Option (2026 Guide)

For patients with knee osteoarthritis who want to delay or avoid total knee replacement, mesenchymal stem cell (MSC) injection therapy in China offers a clinically supervised alternative. Evidence is supportive for pain relief and functional improvement; cartilage regrowth is real but modest. This guide covers hospitals, eligibility, indicative costs, and how to access treatment through China Care Health Tours. For the broader context, see our overview of medical treatment in China for foreigners and stem cell therapy in China.

Key Facts

• At Boao Lecheng, the July 2026 official filed guide prices are RMB 36,350 per injection (single knee) for umbilical cord MSC injection for knee osteoarthritis at Ruijin Hospital Hainan, and RMB 168,000 for a single iPSC cartilage-cell transplant at the same hospital for full-thickness knee cartilage defects. Shulan Boao Hospital delivers UCF, a cell-free cord-blood factor preparation, at RMB 48,000–55,000 per injection. The hip and meniscal items are priced separately, and final figures are confirmed individually after assessment.
• A 2022 systematic review and meta-analysis of 28 randomized controlled trials (1,494 participants) found MSC injection reduced WOMAC pain and VAS scores versus control from 3 months, with the effect sustained at 12 months and no significant difference in adverse events.
• The same review reported a pooled WOMAC pain score reduction of 4.29 points at 12 months versus control, but rated the overall quality of evidence low and cautioned against broad generalisation.
• Treatment requires only 3–7 days in hospital; MSC injection takes 20–30 minutes per knee under local anaesthesia, and patients are ambulatory within 1–2 hours.
• Osteoarthritis affected 595 million people worldwide in 2020, with the knee the most commonly affected joint; knee osteoarthritis alone is projected to rise by about 75% by 2050 (all forms of osteoarthritis by roughly 68%).

Why Patients Seek Alternatives to Knee Replacement

Osteoarthritis of the knee is among the most common joint diseases worldwide. The Global Burden of Disease study puts the 2020 global total at 595 million people living with osteoarthritis, and the knee is the joint most commonly affected. For many, it progresses to the point where standing, climbing stairs, or walking becomes painful enough to disrupt daily life.

The standard endpoint in the conventional treatment pathway is total knee replacement (TKR) — a surgery in which the damaged joint surfaces are removed and replaced with metal and plastic implants. TKR is effective. For severe, end-stage osteoarthritis, it reliably eliminates pain and restores mobility. But for the large segment of patients who have not yet reached that endpoint, or who have significant reasons to delay surgery, TKR carries a set of costs that are not always clearly communicated.

The limitations of total knee replacement:

• Recovery time is substantial. Most patients require 3–6 months of rehabilitation before returning to full activity, and optimal function may not be achieved for a full year post-surgery.
• Implant lifespan is finite. National joint registry data put knee replacement survivorship at around 94–96% at 10 years, roughly 90% still in place at 15 years, and 82% at 25 years. For a 55-year-old with Grade 3 osteoarthritis, this creates a mathematical problem: a revision surgery — significantly more complex than the original — is likely within their lifetime.
• Surgical risk is not trivial. TKR carries risks of deep vein thrombosis, pulmonary embolism, infection, nerve damage, and implant failure. Complication rates are low per case, but for patients with cardiovascular risk factors or elevated BMI, they become clinically significant.
• Not all patients experience full pain relief. A meta-analysis pooling 68 studies and 598,498 knee replacement patients found 12.6% reported unfavourable pain at 12 months. A separate systematic review of total knee arthroplasty outcomes estimates that roughly 1 in 10 patients remains dissatisfied with the result — lower than the often-cited “20%” figure — a phenomenon recognised in orthopedic literature as “chronic post-surgical pain.”
• Functional ceiling. Replaced knees do not perform identically to natural knees. High-impact activities — skiing, running, competitive tennis — are typically contraindicated with implants. For active patients in their 50s and early 60s, this is a meaningful quality-of-life trade-off.

These are not arguments against knee replacement. For Grade 4 osteoarthritis with severe bone-on-bone contact and exhausted conservative options, TKR remains the right intervention. But they explain why a growing number of patients with Grade 2 and Grade 3 disease — part of the 595 million people worldwide living with osteoarthritis — are actively seeking alternatives that can delay or avoid the need for surgery while preserving biological joint tissue.

Mesenchymal stem cell (MSC) therapy is a clinically advanced option among those alternatives currently accessible to international patients.

How Stem Cell Therapy Works for Knee OA

MSC therapy for knee osteoarthritis operates through three overlapping biological mechanisms — each of which addresses a different dimension of the disease.

1. Anti-inflammatory modulation

Osteoarthritis is not simply mechanical wear. It involves a chronic inflammatory process in the synovial membrane and joint space that actively drives cartilage breakdown. MSCs are potent regulators of this inflammatory environment. When injected into the joint, they suppress pro-inflammatory cytokines (including IL-1β and TNF-α) and promote an anti-inflammatory microenvironment. This is the fastest-acting mechanism — many patients report pain reduction within 4–8 weeks of treatment, well before any structural cartilage changes would be measurable.

2. Cartilage regeneration

MSCs have the capacity to differentiate into chondrocytes — the cells that produce and maintain cartilage. When introduced into a damaged joint space, they secrete growth factors (including TGF-β and IGF-1) that stimulate the body’s own chondrocyte activity and promote synthesis of new cartilage matrix. MRI studies in treated patients have documented measurable increases in cartilage thickness at 6–12 months post-injection. The degree of regrowth is modest rather than complete — patients should not expect full cartilage restoration — but even partial regeneration can meaningfully alter the mechanical environment of the joint and slow long-term disease progression.

3. Synovial fluid improvement

MSCs also improve the quality of synovial fluid — the lubricating medium in the joint. Osteoarthritic joints typically have degraded, thin synovial fluid with reduced hyaluronic acid content and elevated inflammatory mediators. MSC treatment has been shown to restore synovial fluid composition, improving joint lubrication and reducing the friction that accelerates cartilage loss.

The cell source matters. Most programs in China use allogeneic umbilical cord-derived MSCs from certified cell banks, which avoids the need to harvest cells from the patient (typically from bone marrow or adipose tissue under anaesthesia). Umbilical cord MSCs are harvested from ethically donated post-birth cord tissue, are highly proliferative, and are considered immunologically “privileged” — meaning they do not require tissue matching and carry minimal risk of immune rejection.

Some programs supplement MSC injection with platelet-rich plasma (PRP) to enhance the growth factor environment, or with hyaluronic acid to restore synovial fluid viscosity. These adjuncts are well-established in orthopedics and complement rather than replace the cellular mechanism of MSC therapy.

Why China for Knee Stem Cell Treatment?

China has become a major global destination for MSC therapy access for several reasons that have less to do with marketing and more to do with regulatory structure, clinical volume, and economics.

Regulatory framework

China’s National Medical Products Administration (NMPA) has established pathways for supervised stem cell clinical research and application. Within the Boao Lecheng International Medical Tourism Pilot Zone in Hainan — China’s designated special medical zone — hospitals are permitted to offer cellular therapies to international patients under supervised clinical protocols, using products approved in the US, EU, Japan, or Australia regardless of their domestic NMPA approval status. This regulatory architecture creates legal, supervised access to treatments that are not commercially available outside clinical trials in the United States or European Union. You can read more in our overview of stem cell therapy in China.

Beyond Boao, several major Chinese cities operate active MSC research programs with high patient volumes and physician teams who have treated a substantial number of MSC cases.

Volume and experience

China runs a large number of stem cell clinical trials, with many active studies specifically targeting musculoskeletal applications. This volume translates into clinical experience — orthopedic teams in China’s established hospitals have administered MSC knee injections to many thousands of patients. Pattern recognition in managing outcomes, side effects, and patient selection is informed by this high case volume.

Cost

The economics of MSC knee therapy in China are straightforward to understand. Treatment is available within an indicative range (see Indicative Treatment Cost in China) that reflects local hospital pricing, cell manufacturing, and clinical oversight. For patients paying out of pocket — which is nearly universal for stem cell therapy regardless of location — understanding the full cost structure in advance is important.

Integration with broader care

Patients traveling to China for knee treatment can simultaneously access executive health screenings, second opinions on other conditions, or consultations across the full hospital network — making the trip medically comprehensive.

Hospitals and Clinics Offering MSC Knee Therapy

Cellular therapy for joints in China is concentrated in one place. Boao Lecheng, in Hainan, is the zone where China’s regulatory framework permits these protocols to be offered and charged for — and the four hospitals below cover the five joint protocols described here — four filed Lecheng cell-therapy items and one cell-free joint-repair technology. Each entry gives the hospital, the published price, and the course.

China Care’s wider hospital directory covers the rest of the network across Shenzhen, Guangzhou, Shanghai, Wuhan and Beijing. None of those hospitals holds a filed Lecheng cell-therapy item, so these specific protocols are not delivered there.

1. Ruijin Hospital Hainan (Boao Lecheng, Hainan)

Ruijin Hospital Hainan is one of the anchor hospitals within the Boao Lecheng International Medical Tourism Pilot Zone and a long-established facility for cellular therapy in the zone. Its MSC knee program uses umbilical cord-derived MSCs from a GMP-certified cell bank, delivered via intra-articular injection under imaging guidance. The hospital has a dedicated international patient department, English-speaking clinical coordinators, and a structured follow-up protocol.

For international patients seeking stem cell knee treatment in a setting that combines clinical rigor, regulatory oversight, and purpose-built international patient infrastructure, Ruijin Hospital Hainan is a primary starting point. The Boao Lecheng zone’s special regulatory status means treatments here operate under a formal supervised protocol — and the knee protocol is one of the zone’s published filed guide prices, not a private quotation.

MSC Knee Program — Lecheng Filed Guide Price: RMB 36,350 per injection (single knee)
Course: 1 injection per course; further injections for severe cases
Stay Required: 3–7 days
Location: Boao, Hainan Province

A second Ruijin knee item: iPSC cartilage cell transplant. Ruijin Hospital Hainan also holds the filed item for iPSC-derived chondrocyte transplantation, and this one is for the knee as well — but for a different problem. Where the MSC injection above targets generalised osteoarthritis, this protocol targets a full-thickness cartilage defect: a focal, structural loss of cartilage, often after injury, rather than wear across the whole joint. The product class differs too — allogeneic chondrocytes derived from induced pluripotent stem cells, implanted surgically rather than injected.

iPSC Cartilage Transplant — Lecheng Filed Guide Price: RMB 168,000 (single transplant procedure)
Course: Single procedure
Location: Boao, Hainan Province

2. Hainan Diwan Hospital (Boao Lecheng, Hainan)

Hainan Diwan Hospital is the hospital named on the Lecheng filed list for hip osteoarthritis. The protocol uses the same allogeneic umbilical cord-derived MSC product as the knee programme, delivered by intra-articular injection under imaging guidance.

Hip OA Program — Lecheng Filed Guide Price: RMB 42,000 per session
Course: 2 sessions (standard course)
Location: Boao, Hainan Province

3. Boao Super Hospital (Boao Lecheng, Hainan)

Boao Super Hospital holds the filed Lecheng item for meniscal injury (M021001), given as a single intra-articular injection. Note the cell source: this is the only musculoskeletal cell-therapy item on the list that uses the patient’s own cells rather than a banked umbilical cord product.

Meniscal Injury Program (M021001) — Lecheng Filed Guide Price: RMB 80,000 per knee
Course: Single procedure (single intra-articular injection)
Location: Boao, Hainan Province

4. Shulan Boao Hospital (Boao Lecheng, Hainan)

Shulan Boao Hospital delivers UCF, a joint-repair preparation developed by PURECELL (Australia) and given as a single intra-articular injection. The identification of this product as UCF rests on the Lecheng deck’s hospital — price — indication match — the deck itself does not name the product — together with PURECELL’s published materials describing UCF knee-repair technology released at Boao Lecheng through Shulan Boao Hospital. This is the one option on this page that is not a cell therapy: UCF is a cell-free extract of cytokines and growth factors derived from donated umbilical cord blood, with no living cells in the preparation. That difference has practical consequences. There is no cell product to bank or match, so the treatment can be scheduled without a manufacturing lead time, and it falls under a different Lecheng approval route from the filed cell-therapy items above.

UCF Joint Repair — Lecheng Franchise Price: RMB 48,000–55,000 per injection
Course: Single injection for most patients; a second injection for some severe cases, billed per injection
Location: Boao, Hainan Province

On the evidence. UCF’s published base is thinner than the MSC literature’s, and it should be read accordingly. The efficacy figures in circulation — including a 97.5% single-injection response rate at 24 months across 140 joints, and several hundred treatments delivered at Shulan since the technology arrived in mid-2025 — come from the manufacturer and its commercial partners rather than from independent randomised trials. UCF has no RCT base comparable to knee MSC therapy. That does not make it ineffective, but the claim is manufacturer-reported, not independently established, and it is presented here on that basis.

Note on the name. UCF is rendered in different sources as Uncharacterized Cartilage Factor and as Umbilical Cord blood Factors. The product itself is the same; the expansion of the acronym is not standardised. Both describe a cord-blood-derived factor preparation, not a cartilage-derived or cell-based one.

Beyond the Knee: Hip and Meniscus Programs

The regulatory framework that makes knee MSC therapy accessible in China covers a wider set of musculoskeletal indications. Two further items appear on the 2026 filed list at Boao Lecheng, delivered at the hospitals above. They matter because patients frequently arrive with more than one joint involved, and because the knee is not always the joint actually driving the pain.

Indication	Lecheng hospital	Filed price (2026)	Typical course
Hip osteoarthritis	Hainan Diwan Hospital	RMB 42,000 per session	2 sessions
Meniscal injury	Boao Super Hospital	RMB 80,000 per knee	Single procedure

Filed prices are the 2026 Lecheng published list figures. They are set and billed by the treating hospital and confirmed individually after medical review. The hospitals bill in RMB, so no converted figure is given here.

Hip osteoarthritis. The hip is the second most common site for MSC joint therapy, and the clinical problem is the same as the knee: cartilage loss, synovial inflammation, progressive pain on weight-bearing. The same allogeneic umbilical cord MSC product is used, delivered by intra-articular injection under imaging guidance. What differs is the evidence base. Far fewer randomised trials exist for the hip than for the knee, and the published results are more variable. Patients should weigh hip MSC therapy as a less-evidenced intervention than the knee equivalent, and should be cautious of any provider that presents the two as clinically interchangeable.

Meniscal injury. A torn meniscus is a structural injury rather than a degenerative disease, and it behaves differently. The inner two-thirds of the meniscus has almost no blood supply, which is why it heals poorly on its own and why partial meniscectomy remains the standard surgical answer. Cell-based approaches aim to support repair and to slow the joint degeneration that follows meniscal loss. The filed item exists and the biological rationale is reasonable, but the published clinical evidence is substantially earlier than for knee osteoarthritis. This is a reasonable line of enquiry for a patient facing meniscectomy who wants to understand the alternatives; it is not a settled substitute for surgery.

Eligibility review, treatment process, follow-up and pricing mechanics for these indications follow the same pattern described in the sections below. The clinical assessment still comes first, and nothing is confirmed until the treating hospital has reviewed your imaging.

Who Qualifies?

MSC knee therapy is not appropriate for every patient with knee pain. The following table outlines standard eligibility criteria applied by treating physicians in China’s established programs:

Criterion	Details
OA Grade	Grade 2–4 on Kellgren-Lawrence scale; Grade 2–3 shows strongest evidence; Grade 4 (bone-on-bone) may still benefit but with more modest cartilage outcomes
Age	40–75 years old (varies by protocol; younger patients tend to show stronger regenerative response)
BMI	Under 35 preferred; patients with BMI 35–40 assessed case by case with emphasis on weight management co-intervention
Prior treatments	Should have completed a course of conservative management (physiotherapy, NSAID/corticosteroid trials, PRP or hyaluronic acid injection)
Surgical history	Previous knee arthroscopy is acceptable; prior TKR on the same joint is typically a contraindication
Systemic conditions	Controlled diabetes, hypertension, and cardiovascular disease are acceptable; active infection, active malignancy, and autoimmune disease on immunosuppressive therapy are exclusions
Imaging	Weight-bearing X-ray and MRI within 12 months required; MRI cartilage assessment is key for treatment planning
Patient goals	Pain relief and functional improvement are realistic expectations; full cartilage restoration is not

Patients who have recently received corticosteroid injections into the affected knee are typically asked to wait 4–6 weeks before MSC treatment, as steroids can suppress the stem cell activity.

The most important eligibility filter is clinical assessment by the treating team, not a checklist. Borderline cases — high BMI, Grade 4 disease, prior surgical history — should go through a thorough pre-treatment review rather than self-excluding.

The Treatment Process: What to Expect

One of the significant practical advantages of MSC knee therapy over total knee replacement is the brevity of the in-hospital stay. While TKR requires 4–7 days of inpatient care followed by months of rehabilitation, MSC knee treatment is typically completed in 3–7 days with no surgical anaesthesia and minimal downtime.

Step 1 — Pre-treatment assessment (Day 1)

On arrival, patients undergo baseline evaluation: knee X-rays (weight-bearing), MRI review, blood panel (inflammatory markers, CBC, metabolic screen), and a clinical examination by the treating orthopedic physician. The assessment confirms eligibility and establishes the baseline against which outcomes will be measured. Some protocols include synovial fluid aspiration for cytokine profiling.

Step 2 — Stem cell preparation

Most programs use allogeneic umbilical cord-derived MSCs from a certified cell bank. The cells arrive at the facility pre-prepared and undergo quality testing before administration — no bone marrow harvest under anaesthesia is required. Some programs offer autologous adipose-derived MSCs (harvested from the patient’s own fat tissue under local anaesthesia); this option takes an additional 2–4 days for cell processing.

Step 3 — Intra-articular injection (Day 2–3)

MSC injection is performed under ultrasound or fluoroscopic guidance to ensure precise intra-articular placement, typically taking 20–30 minutes per knee with local anaesthesia only.

MSCs are injected directly into the knee joint space under ultrasound or fluoroscopic guidance. The procedure takes 20–30 minutes per knee and uses local anaesthesia only — no general anaesthesia, no incision. Patients are ambulatory within 1–2 hours of the injection. Some protocols administer 1–2 sessions; others use 3 injections spaced over several days for a higher cumulative cell dose.

Step 4 — Adjunct therapies (Days 2–5)

Many programs combine the MSC injection with:

• PRP (platelet-rich plasma) injection — administered simultaneously or sequentially to enhance the growth factor environment
• Hyaluronic acid viscosupplementation — to improve synovial fluid quality
• Physiotherapy — 1–2 sessions of guided exercise prescription during the stay to support early tissue remodeling

Step 5 — Discharge and follow-up

Patients are discharged with a structured follow-up protocol: clinical review at 4–6 weeks, MRI and functional assessment at 6 months, and clinical follow-up at 12 months. During the first 2–4 weeks post-injection, patients are advised to avoid high-impact activity (running, jumping) while maintaining low-impact movement (walking, cycling, swimming) to support cell integration.

China Care coordinates all post-discharge follow-up communication between the treating hospital and the patient’s home physician.

What the Evidence Shows

Intellectual honesty is important here. The evidence base for MSC therapy in knee osteoarthritis is real, growing, and meaningfully positive — but it is not the same quality of evidence that supports hip or knee replacement, and patients should understand what it does and does not show.

What the evidence consistently supports:

• Pain reduction: Multiple randomized controlled trials have demonstrated statistically significant reductions in KOOS (Knee injury and Osteoarthritis Outcome Score) and VAS pain scores at 6 and 12 months post-injection. A 2022 systematic review and meta-analysis of 28 randomized controlled trials, covering 1,494 participants, found that MSC injection reduced WOMAC pain and VAS scores versus control from 3 months, with the effect sustained at 12 months and no significant difference in adverse events. The authors rated the quality of the included evidence low and cautioned against broad generalisation.
• Functional improvement: KOOS function, WOMAC scores, and 6-minute walk test results consistently improve in treated patients. These are patient-reported and functional outcomes that directly reflect quality of life.
• Safety: MSC therapy has a robust safety profile in musculoskeletal applications. Serious adverse events are rare; the most common side effects are transient joint swelling and mild discomfort in the 24–72 hours post-injection.
• Durability: 24-month follow-up data from published trials shows maintained pain and function benefits in most responders. Some studies report sustained benefit at 5 years.

What the evidence is less clear on:

• Structural cartilage regrowth: MRI studies do show measurable increases in cartilage thickness in treated patients, but the degree varies widely and some studies show minimal structural change despite clear clinical improvement. It appears that the anti-inflammatory and pain-relief effects are more reliably reproduced than full cartilage regeneration.
• Grade 4 outcomes: Patients with severe bone-on-bone osteoarthritis show less consistent results. MSC therapy for Grade 4 should be framed as a possible delaying strategy or adjunct to other interventions rather than a replacement for surgery.
• Optimal protocol: The field has not yet converged on a standard protocol for cell dose, injection frequency, cell source, or adjunct therapy combination. Programs vary, and this creates difficulty in comparing outcomes across centers.

The honest summary: MSC knee therapy is a clinically validated intervention with a strong evidence base for pain relief and functional improvement. It is not a guaranteed cure, it does not reliably restore full cartilage architecture, and it is not the right choice for every patient. For patients with Grade 2–3 osteoarthritis who are seeking to delay or avoid surgery while meaningfully improving quality of life, the evidence is sufficiently strong to justify serious consideration.

ClinicalTrials.gov currently lists many active MSC knee osteoarthritis trials globally — a substantial share based in China — which reflects where the evidentiary frontier is being pushed.

Indicative Treatment Cost in China

At Boao Lecheng — the zone where China’s regulatory framework makes cell therapy chargeable — the July 2026 official filed guide prices for knee protocols are RMB 36,350 per injection, single knee (umbilical cord MSC, Ruijin Hospital Hainan) — consistent with the Lecheng first-batch published price of RMB 36,000 per injection for umbilical-cord MSC knee osteoarthritis treatment — and RMB 168,000 per single procedure (iPSC cartilage-cell transplant, same hospital). The other joint protocols — UCF at Shulan Boao (RMB 48,000–55,000 per injection, cell-free), the hip protocol at Diwan and the meniscal protocol at Boao Super — are priced separately, and final figures depend on cell source, number of injections, adjunct therapies, and length of stay. Treating hospitals bill in RMB, so no converted figure is given here.

How pricing works

• Hospital fee: At Lecheng the figure is the zone’s filed guide price for the named protocol, and it covers the clinical protocol, cell product, imaging-guided injection, and structured follow-up. China Care applies zero treatment markup to it.
• Coordination fee (separate): China Care applies a separate coordination fee for medical navigation, translation, and logistics. This is quoted after a free eligibility review and is distinct from the hospital fee.
• Confirmed individually: Final figures are confirmed on a case-by-case basis and may differ from the indicative range. For current, personalised pricing, message us on WhatsApp.
• Filed guide price, not a fixed quote: All figures are the July 2026 Lecheng official filed guide prices. Confirm against the hospital’s published price on the day of treatment: fees can change with operating costs and consumable adjustments. Pre-treatment screening such as genetic testing and imaging assessment is billed separately.

This is a guide, not a fixed quote. Treatment costs vary by protocol, hospital, and individual assessment.

For context on total out-of-pocket planning: self-pay prices for total knee replacement in the United States commonly fall between US$20,000 and US$75,000, and exceed US$100,000 at some hospitals, with a significantly longer recovery timeline. Patients often consider a trial of supervised non-surgical therapy before committing to surgery. All pricing discussed here is indicative and confirmed individually.

How to Access Treatment as an International Patient

Step 1 — Gather Your Imaging and Medical Records

Before any consultation, assemble:

• Weight-bearing knee X-rays (AP and lateral, both knees if bilateral) — ideally within 12 months
• MRI of the affected knee(s) — cartilage sequencing preferred
• Summary of current symptoms: pain level, functional limitations, duration
• List of prior treatments: physiotherapy, injections, medications
• Current medications and any relevant comorbidities

If your imaging is older than 18 months, you may be asked to obtain updated scans before the clinical team can complete an eligibility assessment.

Step 2 — Clinical Eligibility Review

Submit your records to China Care Health Tours for a pre-treatment review. The treating team — typically an orthopedic physician or regenerative medicine specialist — will assess your OA grade, clinical profile, and prior treatment history. You will receive a written eligibility assessment and preliminary treatment plan within 3–5 business days.

This review is conducted before you commit to travel or incur any costs.

Step 3 — Visa and Travel Planning

Most MSC knee treatment stays are 3–7 days — short enough for some nationalities to enter China under the 240-Hour Visa-Free Transit policy (available at major airports). For longer stays, patients traveling to Hainan for Boao Lecheng treatment can use Hainan’s 30-day visa-free entry available for many nationalities.

For patients who require a formal medical visa, China Care prepares the documentation. Full guidance is available in our complete 2026 guide to China medical visas. If you need language support during your stay, see our guide on hiring a medical translator in China.

Step 4 — Arrive and Begin Treatment

China Care provides a bilingual patient coordinator throughout your hospital stay — from airport transfer and hospital admission through to specialist appointments, injection days, and discharge documentation. All communication between you, the clinical team, and your home physician is managed.

Step 5 — Post-Treatment Follow-Up

The therapeutic effect of MSC knee injection develops over weeks to months as the biological processes unfold. Patients should plan for:

• Weeks 1–4: Avoid high-impact activity; continue low-impact movement; monitor for any unusual swelling or discomfort
• Month 1–2: Most patients notice measurable pain reduction
• Month 6: MRI re-assessment to evaluate cartilage response
• Month 12: Full clinical review and outcome assessment

At each milestone, China Care coordinates communication between your treating hospital in China and your local orthopedic physician or physiotherapist. Digital copies of all clinical documentation, imaging, and treatment records are provided in English.

Frequently Asked Questions

Is stem cell therapy for knee osteoarthritis available outside clinical trials in China?
Yes — particularly within Boao Lecheng International Medical Tourism Pilot Zone, where the special regulatory framework permits supervised MSC therapy for international patients. Major academic hospitals in several Chinese cities also offer access through clinical research protocols.

How does MSC therapy differ from PRP (platelet-rich plasma) injections?
PRP delivers concentrated growth factors from the patient’s own blood and is a well-established, more modest intervention. MSC therapy goes further: it delivers living cells with regenerative, anti-inflammatory, and differentiating capabilities that PRP does not provide. Many programs in China combine both, using PRP to enhance the environment into which MSCs are introduced.

How long before I notice improvement?
Anti-inflammatory effects can produce noticeable pain reduction within 4–8 weeks. Functional improvement tends to be more pronounced at 3–6 months as cellular activity peaks. Cartilage changes, if they occur, are visible on MRI at 6–12 months.

Can I treat both knees at once?
Many programs offer bilateral knee treatment in a single session or over consecutive days, which is logistically convenient for international patients. Your treating physician will assess whether simultaneous bilateral treatment is appropriate based on your overall health status.

What happens if the treatment does not work?
Published trials report group-level improvements in pain and function that are maintained at 12 months in most patients, though individual response varies and the quality of the included evidence is rated low. For non-responders, the treatment does not accelerate disease progression and does not preclude subsequent knee replacement. MSC therapy does not “burn the bridge” to surgery.

Is the treatment painful?
The injection itself is performed under local anaesthesia and is typically well-tolerated. Patients often report mild aching or swelling in the treated joint for 24–72 hours post-injection. This typically resolves without intervention. Serious adverse events (infection, severe immune reaction) are rare in published literature.

Will my insurance cover this?
In most countries, MSC therapy for knee osteoarthritis is not covered by standard health insurance as it has not received routine commercial approval. This is also true inside China: none of the 58 cell and gene therapy technologies on the Lecheng list is covered by China’s national medical insurance scheme, so the entire cost is self-paid. Treatment is a direct out-of-pocket cost, paid to the treating hospital rather than to China Care. Some patients use health savings accounts or medical financing.

Can the same trip treat my hip as well as my knee?
Often, yes. Hip and knee protocols exist at Lecheng centres and can be scheduled within a single stay, subject to the treating physician’s assessment of your overall status and how you tolerate the first procedure. One caveat worth stating plainly: the evidence base for the hip is thinner than for the knee. We would rather you understood that difference before deciding than discovered it afterwards.

Is stem cell therapy for a torn meniscus an alternative to surgery?
Not a settled one. The filed Lecheng item exists and the biological rationale is reasonable, but published evidence for cell-based meniscal repair is much earlier than for knee osteoarthritis. Where a tear is causing mechanical locking, or where conservative care has failed, surgical assessment remains the standard first step. MSC therapy is worth exploring as an addition or a later option, not as a routine replacement.

Last updated: October 2026.

References

1. Wikipedia. “Osteoarthritis.” Wikipedia, the Free Encyclopedia. https://en.wikipedia.org/wiki/Osteoarthritis
2. ClinicalTrials.gov. Active MSC knee osteoarthritis trials, many based in China. https://clinicaltrials.gov/
3. National Medical Products Administration (NMPA). Regulatory framework for stem cell clinical research and Boao Lecheng special zone. https://www.nmpa.gov.cn/
4. Long Z, Zhang M, Zhang T, Zeng L, Yang K, Yang T, et al. “The Effectiveness and Safety of Mesenchymal Stem Cells in the Treatment of Osteoarthritis: A Systematic Review and Meta-analysis of 28 Randomized Controlled Trials.” Stem Cells International, 2022;2022:6151866. https://doi.org/10.1155/2022/6151866
5. Kellgren-Lawrence Grading Scale. Standard radiographic grading for knee osteoarthritis severity. (Referenced in eligibility table.)
6. KOOS (Knee Injury and Osteoarthritis Outcome Score) and WOMAC (Western Ontario and McMaster Universities Arthritis Index). Patient-reported outcome measures referenced in clinical trial data.
7. China Care Health Tours. “Stem Cell Therapy in China.” https://chinacarehealthtours.com/stem-cell-therapy-in-china/
8. China Care Health Tours. “Executive Health Screening.” https://chinacarehealthtours.com/executive-health-screening/
9. China Care Health Tours. “How to Get a Medical Visa for China.” https://chinacarehealthtours.com/how-to-get-a-medical-visa-for-china-a-complete-2026-guide/
10. Steinmetz JD, et al. “Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021.” The Lancet Rheumatology, 2023;5(9):e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7
11. Cheng HY, Beswick AD, Bertram W, Siddiqui MA, Gooberman-Hill R, Whitehouse MR, Wylde V. “What proportion of people have long-term pain after total hip or knee replacement? An update of a systematic review and meta-analysis.” BMJ Open, 2025;15(5):e088975. https://doi.org/10.1136/bmjopen-2024-088975
12. DeFrance MJ, Scuderi GR. “Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature.” Journal of Arthroplasty, 2023;38(3):594–599. https://doi.org/10.1016/j.arth.2022.10.011
13. UK National Joint Registry. Implant survivorship and revision rates for primary knee replacement. https://www.njrcentre.org.uk/